Affilogic is a private biotech company specialized in discovering and developing Nanofitins®-based therapeutics, through in house programs or collaborations with worldwide industry leaders in the pharmaceutical sector.
Recent news :
May 2024 – Affilogic takes part in the NAVIPP Project : Since beginning of 2024, Affilogic is a member of the NAVIPP project. The consortium will implement a strategic, multi gear R&D and clinical roadmap for the identification, optimisation, preclinical and clinical investigation of broad-spectrum antivirals against pathogens with epidemic or pandemic potential.
Jan 2024 – Iconovo to present positive data from a feasibility study on Nanofitins® in ICOone®: Iconovo AB and Affilogic today announce that Iconovo will present positive results from a feasibility study with a Nanofitin®-based biologic drug against respiratory virus using ICOone®. The study results will be presented at Respiratory Drug Delivery (RDD®) 2024, which takes place in Tucson, Arizona, on May 5-9, 2024.
Around the world
BiotechShowcase 2025
Affilogic will attend next BiotechShowcase in San-Francisco – USA
Jan 13-15, 2025
I4ID Lyon 2024
Affilogic presenting at 8th I4ID in Lyon – France
Nov 27-28, 2024
BIO EUROPE 2024
Affilogic will attend next BIO EUROPE in Stockholm – Sweden
Nov 4-6, 2024
Nanofitins
Each Nanofitin® is 20 times smaller than an antibody and demonstrates hyper stability. Their simple protein scaffold is particularly fitted for combination.
Read More
Our Programs
Affilogic develops therapeutic programs leveraging unique Nanofitins’ properties for brain delivery, inhalation of antivirals, oral GI treatments or small size drug conjugates.
Read More
NanoVector
Affilogic works with partners to deliver their therapeutic compounds to specific cells / organs with existing Nanofitins® or through custom generation of Nanofitins®.
Read More